3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
9
pembrolizumab
6
Ipilimumab
5
Magnetic Resonance Spectroscopy
3
resiquimod
2
encorafenib
2
binimetinib
2
aldesleukin
2
Oncolytic Virotherapy
2
MART-1 Antigen
2
Interleukin-2
2
Cyclophosphamide
2
urelumab
1
tremelimumab
1
tetraethylpyrazine
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
relatlimab
1
montanide ISA 51
1
glucopyranosyl lipid-A
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
clevudine
1
cemiplimab
1
avelumab
1
Specimen Handling
1
Sentinel Lymph Node Biopsy
1
S 28463
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Melanoma
×
RXDX-106
×
Clear all
NCT03454243
2019-04-25
TITAN
Hoffmann-La Roche
Phase EARLY_PHASE1
Terminated
1 enrolled